South Korea Acne Medication Market

South Korea Acne Medication Market Summary

As per Transpire Insight Analysis the South Korea Acne Medication Market size is estimated at USD 177.8 Million in 2025 and is anticipated to reach USD 376.3 Million by 2033, growing at a CAGR of 9.83% from 2026 to 2033.

South Korea has a steady acne care market. Pharmacies, skin clinics, and other care providers sell and recommend treatments. Many patients rely on both creams and tablets. The aim is to calm active breakouts. It also helps with redness and swelling. Another goal is to lower the odds of new acne later.

Over the past few years, choices have shifted. People want options that fit their specific problem. Doctors often point patients toward prescription retinoids. Some use combined therapy plans. Others choose topical products that have clear study support. Side effects are still a concern, though. How well a product is tolerated can decide what gets picked.

After COVID-19, routines changed for many. Wearing face masks caused irritation for some people. Those same people then sought more acne support. This helped drive interest in skincare and dermatology care that is simpler to get.

More recently, buyers have leaned toward treatments that both work and are easy to follow. This pattern shows up strongly in younger groups.As more dermatology visits happen, and as pharmacy and online health paths expand, makers can reach people in more than one route. The rise in market revenue suggests care that is better matched to each patient. It can also mean new product directions. It can mean broader access too. The focus is not just on higher sales.

South Korea Acne Medication Market Size & Forecast:

• South Korea Acne Medication Market Size 2025: USD 177.8 Million
• Expected Market Value 2033: USD 376.3 Million
• Forecast CAGR: 9.83%
• Leading region in 2025: 
• Fastest Growing region: 
• Key Profile: Galderma, Johnson & Johnson, Bausch Health, AbbVie, Pfizer, Viatris, Bayer, Teva Pharmaceutical Industries, Sun Pharmaceutical Industries, Hanmi Pharmaceutical, Dong-A ST, Chong Kun Dang, Daewoong Pharmaceutical, Yuhan Corporation, JW Pharmaceutical 

Key Market Insights

• The Seoul area takes the largest slice of South Korea’s acne drug sales. In 2024, it is about 45% of the market. This is helped by a strong skin-care system and many dermatology sites.
• Gyeonggi is moving ahead faster than the other areas. It is expected to grow the quickest through 2031. More skin clinics are opening there. There are also more younger people. Drug access through more pharmacies is wider as well.
• Topical products are the main type. They make up around 69% of the market. Doctors already prescribe them often. They are also simpler for patients to use, even when acne is mild or more severe.
• Prescription medicine ranks next. This group holds the second spot by size. It is backed by care led by dermatologists. Retinoids and combo treatment plans are already well used.
• Retinoids are projected to grow the most by 2030. Newer options are helping this trend, including trifarotene. Doctors also keep using combo plans that include retinoid steps.
• For acne types, inflammatory acne leads. It is roughly 55% of the indication share. This keeps antibiotic options, retinoid use, and combo regimens in steady demand for moderate acne.
• Online pharmacies look set to grow fastest by 2030. Buying online is getting easier. People can find products without relying only on clinic visits.
• Dermatology clinics are still the biggest end-user channel. They hold about 40% share. This ties to prescription diagnosis, follow-up checks, and meds linked to in-clinic procedures.
• Online pharmacies also lead among end-user categories. Digital check-ins help patients learn about products. Repeat buys are becoming part of the routine too.
• Galderma added more prescription acne options in Korea. It expanded Aklief and brought trifarotene into its existing lineup that already includes Differin and Epiduo.

What are the Key Drivers, Restraints, and Opportunities in the South Korea Acne Medication Market?

Seoul accounts for the biggest share of acne medicine sales in South Korea. In 2024, the figure is around 45 percent. This comes from a solid skin care scene and a high number of dermatology clinics. Gyeonggi is picking up pace faster than the rest. Through 2031, it is expected to be the fastest growing region. Clinics keep opening there, and the area has more younger residents too. Access to drugs is also easier since more pharmacies are available.When it comes to product type, topical care is the main category. It makes up about 69 percent of the market. Many doctors already use it in daily practice. It also tends to be easier for patients to follow, whether acne is mild or not.

Prescription acne medicine comes in next. This segment sits in second place. It is supported by dermatologist-led treatment. Retinoids and mixed treatment plans are used a lot already.By 2030, retinoids are expected to rise the most. Newer options are pushing that trend forward. Trifarotene is one example. Doctors also keep using combination plans that include retinoid steps.Looking at acne categories, inflammatory acne leads. It takes up about 55 percent of the indication share. Because of that, antibiotics, retinoid use, and combination routines keep steady demand for moderate acne.

Online pharmacies are likely to grow fastest by 2030. Online buying is becoming simpler. People can locate products without relying only on clinic visits.Even so, dermatology clinics remain the top channel for end users. They hold roughly 40 percent of the share. This links to diagnosis through prescriptions, follow up visits, and medicines tied to in clinic procedures. For end users, online pharmacies are also leading in their own way. Digital check-ins help patients understand what to use. Repeat purchases are starting to feel normal as well.Galderma added more prescription acne products in Korea. It expanded Aklief. It also brought trifarotene into its current set, which already includes Differin and Epiduo.

What Has the Impact of Artificial Intelligence Been on the South Korea Acne Medication Market?

AI is changing acne care. Instead of choosing a product now and then, people are being pushed toward plans that get adjusted over time. In South Korea, some acne apps already use AI while users take photos, report what they put on their skin, and note daily habits. Those small check-ins can become a clear timeline. Then a doctor can look at it during a visit.

Some of these tools also try to guess how a routine will turn out. They look at close images of spots. They may also use past logs, severity ratings, and signs that a person is actually staying with the plan. With enough records, the system can make a best estimate of how the skin may respond. In 2025, a randomized trial was published. It said AI suggestions produced a better Investigator Global Assessment score than a plan picked by the patient by itself. The study team described the results as a clinical helper for adjusting care.

On the operational side, phone based tracking could lower the amount of manual work for clinic staff. It may also spot cases that need a tweak sooner. That would mean less waiting until the next scheduled appointment.Separate Korean research has covered AI tests in dermatology on large collections of data. It pointed to studies that used more than 152,000 hospital images and over 1.69 million web app requests. That kind of scale shows what image based systems can handle.Even so, there is a major weak area. Validation quality is not consistent. A review in 2024 said many AI dermatology apps lacked strong clinical support. It also raised issues with unclear testing steps, low input from clinicians, and privacy safeguards. Because of these gaps, the tools may not plug in right away to regulated medication systems.

Key Market Trends

• From 2021, trifarotene entered as a newer retinoid option, and it made the acne market more competitive. It also pushed focus on selective action and treatment for trunk acne.
• In 2024, JW ShinYak rolled out Dicne Cream, which uses nadifloxacin. This suggested fresh movement in local prescription acne creams.
• For 2022, topical products kept a 68.6% share in Asia Pacific. The same period still showed a strong preference in Korea for easy, localized use.
• In 2022, retinoids were 33.6% of the Asia Pacific share. Newer retinoid molecules were also starting to separate from older approaches, not only antibiotics for acne.
• Prescription medicines reached 65.3% in Asia Pacific in 2022. This backed the idea that dermatologists still lead treatment in South Korea.
• In 2022, pharmacies and drug stores made up 49.6% of Asia Pacific distribution. At the same time, online sales kept rising in importance.
• By 2025, machine learning personalization had more clinical support. In an 8 week randomized trial, tailored suggestions did better than choices made by patients on their own.
• In Korea, AI dermatology work sped up. In 2025, 152,443 hospital images were used to support tests for large scale skin disease models.
• After 2024, scrutiny grew for AI apps. That research pointed to weak proof in some cases, privacy issues, and uneven checks across 41 dermatology applications.
• Combination therapy also mattered more. Korean evidence showed adapalene 0.3% plus benzoyl peroxide improved acne results over 24 weeks.

South Korea Acne Medication Market Segmentation

By Product Type : 

Product recommendations keep changing based on the acne type and how easily someone’s skin reacts. A lot of dermatologists still begin with topical retinoids. These can help with blocked pores, and they can also calm red, puffy spots. Some patients will end up with more than one option, because one plan may not solve every acne trigger.

Benzoyl peroxide and salicylic acid are still common in drug stores and in skin clinics. They have been used for a long time. They also come in formats people can find without too much trouble. For inflamed acne, clinicians still reach for antibiotics in some cases. Isotretinoin is kept for the toughest situations, and it is prescribed under close supervision. Azelaic acid is getting more attention, and so are treatments tied to hormones. Newer blended formulas are also showing up more often. Doctors want choices that feel okay during use, and they want outcomes that fit what each person actually needs.

By Acne Type : 

How you deal with a spot on the skin depends on a few things. The key parts are how bad it is, how much swelling there is, and how inflamed it looks. It also matters if the spot returns again and again. Then there is the question of what sets it off in the first place.

For mild to moderate acne, a lot of people begin with products from a pharmacy or from a skin clinic. So creams and gels are often the first option. Many patients use those for some time before they change course.With more inflamed acne, medicine is also used a lot. The reason is usually the look of it. Redness, swelling, and painful bumps can mean the treatment should focus on what is going on at that moment.

When acne turns severe, with cysts or nodules, the picture shifts. More people need specialist care, and prescriptions become more common. For tough cases, isotretinoin and mixed treatment plans still play a key role. For acne that is tied to hormones, care tends to focus on the hormone driver. If clinicians match the diagnosis to the right plan earlier, patients may shift away from generic over the counter products. This shift can be seen more in those who want quicker relief and steadier results.

By Route of Administration : 

Applying treatments on the skin stays important. Creams, gels, lotions, and solutions let clinicians treat the spots directly. Options like topical retinoids, benzoyl peroxide, salicylic acid, and azelaic acid can be used for many cases, from mild to moderate acne. Clinics and pharmacies will keep using these skin options since they fit office care and also work for regular home routines.

Oral therapy also matters, mainly for moderate to severe acne. With oral antibiotics and isotretinoin, patients need more medical checks. That means the plan for prescribing is tied more closely to visits with dermatology. Combination approaches are likely to be used more often. Clinicians want better control of inflammation, clogged pores, and later return of symptoms, but they also try to keep the length of treatment and side effects in mind.

By End User : 

Dermatology clinics are still a main place for skin care. A doctor can look at the rash or bump and name the problem. Then the right medicine is easier to choose. After that, refills can be tracked better. Later checks also become more straightforward.When it gets more complex, hospitals and specialty centers step in. These problems often need tight monitoring by a trained team. Sometimes the care plan must involve more than one step or service.

Pharmacies help with day to day access. For common needs, people can pick up the topical products they already use. Refills can also happen on time, without as much waiting.Home routines matter a lot for acne. Most acne plans rely on daily product use. Even when people do everything right, change may take weeks or even months.Online pharmacies may rise in use as well. More shoppers may choose the web as browsing and online advice feel simpler. Reordering can also feel less work. Reminders for treatment can be easier to set. Some items, both prescription and over the counter, may be easier to locate.

By Distribution Channel : 

Retail drugstores are still a solid option for common skin creams and over the counter acne products. If someone needs a prescription, hospital pharmacies and dermatology clinics matter more. They help with proper diagnosis and with follow ups during treatment. What channel gets chosen usually depends on how bad the acne is, whether a prescription is needed, what is in stock, and what the patient wants.

Online pharmacies are likely to grow faster because people can get help online and then order the product for delivery. Some brands also do well with direct selling when they want a tighter link with buyers. Still, clinics and hospital channels stay useful for care led by specialists. Companies also need a planned way to ship products so customers can buy through both online and in person options.

What are the Key Use Cases Driving the South Korea Acne Medication Market?

Creams and gels for acne are still the go to approach. This matters a lot when the acne is not severe, like mild to moderate cases. Many people pick these products up at a pharmacy. Some also go through skin clinics.

Dermatologists and pharmacists often point patients toward topical care. It is also what many patients want to use. You put it on each day. Then you stick with it for weeks. That feels easier than pills, and it does not ask for a lot of extra steps. Products you will commonly see include retinoids, benzoyl peroxide, and mixed options that combine more than one ingredient.

In hospital units and specialty practices, topical use is also on the rise, even for tougher cases. When acne is severe, it usually needs closer follow up. Doctors may suggest oral antibiotics or isotretinoin. With either option, patients need check ins while treatment is ongoing. Specialty clinics manage this kind of care more often. Some people also use online pharmacies. They order from home, which is convenient. After they speak with a clinician, they may place another order later.

At the same time, new tools are starting to appear. Some systems aim to help people choose products and watch how skin changes. Clinics and remote care teams can use photos to see progress over time. Then they can decide what to adjust next. This could help plans fit each person a bit better.

Which Regions are Driving the South Korea Acne Medication Market Growth?

Seoul’s metro region is in first place. In 2024, the market share is thought to be about 45%. A big reason is the area has many dermatology clinics and hospitals. It also has a high number of pharmacies and specialty care sites. With that coverage, patients can be seen earlier. Getting prescriptions is also smoother. Follow ups for different acne levels can happen more often and in a closer way.Galderma sells several skin care drug options in Korea. Its line in this market includes Aklief, Differin, and Epiduo. At the same time, local drug makers offer prescription choices through clinic and pharmacy routes that already work. Because of this, Seoul should stay ahead up to 2033. Matching the same reach is hard. So is copying the specialist setup and the way drugs move through the system at that size.

Busan and the wider southeast metro belt follow another model. The money base is backed by a large city population. The region also has well known hospitals and a steady retail pharmacy network. Since care is easy to reach, doctors can prescribe more often. This does not rely on the same high density of specialists found in Seoul. Regional hospitals and dermatology clinics still pull repeat visits for treatment. Retail pharmacies also help people get common topical products. Health spending that continues, plus long term links in distribution, should keep the area active through 2033. This matters most for prescription drugs and the treatments that flow through pharmacies.

Gyeonggi is expanding quickly. New residents are arriving. Homes are being built at a steady pace. More health centers are opening too. As this continues, daily movement and care routines are shifting away from central Seoul.The region also already has clinics. JW Shinyak operates there today. The firm is in Gwacheon. It has deep know-how in dermatology. It also stays focused on medicines and prescriptions.If more clinic rooms open up, and medicine deliveries get easier, there is space for fresh treatment brands. This could also help change how prescriptions are handled. It may allow more specialist type care. Between 2026 and 2033, fresh players and investors may view Gyeonggi as a reasonable place to begin. New local systems can pull in more patients. At the same time, the fees of being in central Seoul may be lower for them.

Who are the Key Players in the South Korea Acne Medication Market and How Do They Compete?

The market is not ruled by one clear leader. Large global dermatology companies face off with Korean drug makers. There are also smaller local manufacturers, but they tend to matter most when it comes to prescription supply.Cost is not the main deciding factor here. Clinicians want evidence from real clinical use. Doctors also care about steady availability. On top of that, product traits count. This covers how the drug is manufactured. It also covers how it performs. It includes how the brand is shared through doctors and through the distribution path.

Many firms try to keep what they have. Some older companies expand their product range so they can meet more needs. Other local players go the other way and keep their focus tighter. They build close links with specific clinics. They also improve formulations. Over time, that can lead to smaller niches that still stay loyal.Galderma runs its plan around skin-focused, differentiated products. It does not lead with the cheapest price. Instead, it adds more options for doctors. Aklief now contains trifarotene, a topical retinoid that targets RAR-γ. Galderma also sells Differin and Epiduo. With acne care products that fit different treatment needs, it supports stronger prescribing by specialists and gives more selection.

JW Shinyak operates with a local clinic-centered approach. It leans on ties with physicians. It also works on formulation updates and “open” collaboration. With that setup, doctors may find it simpler to use JW Shinyak products. It also supports changes that fit local use.Hanmi Pharmaceutical tries to stand out through skin-focused development. It also depends on pharmacy reach so the brand stays visible. Dong-A Socio Group leans on branded dermatology items. It also leans on domestic distribution, which helps it show up more often with consumers and at pharmacies.Overall, these steps keep rivals looking at how well treatments work. They also push formulation quality, links to specialists, and the way products move through the channel. Price remains less important than the rest.

Company List

• Galderma
• Johnson & Johnson
• Bausch Health
• AbbVie
• Pfizer
• Viatris
• Bayer
• Teva Pharmaceutical Industries
• Sun Pharmaceutical Industries
• Hanmi Pharmaceutical
• Dong-A ST
• Chong Kun Dang
• Daewoong Pharmaceutical
• Yuhan Corporation
• JW Pharmaceutical 

Recent Development News

• In October 2025, Cosmo Pharmaceuticals secured South Korean approval for Winlevi® (clascoterone) cream 1%. The MFDS authorization introduced a first-in-class topical androgen-receptor inhibitor for acne patients aged 12 and older, with Hyundai Pharma holding exclusive Korean commercialization rights. Source https://www.cosmohealthconfidence.com/
• In January 2026, Hyundai Pharm prepared for the Korean launch of Winlevi® following its partner Cosmo Pharmaceuticals’ Phase 3 clascoterone results. The development strengthened expectations for commercialization of a differentiated acne therapy while expanding Hyundai Pharm’s dermatology portfolio. Source https://en.sedaily.com/culture/

What Strategic Insights Define the Future of the South Korea Acne Medication Market?

Over the next five to seven years, acne care is likely to shift from chasing more units sold. Gains will come more often from options that feel different in use, and that carry support from prescription dermatology. Patients should end up with plans that match their own skin, not a one size fit all approach. Digital follow ups may also take on a larger role.

A main reason is “treatment upgrade.” Both patients and clinicians often lean toward products with a clear medical fit. They also want better comfort and less chance of side effects. In many situations, they prefer a known method that targets the main issue, not just ingredients that people already recognize.

There is also a less visible threat. When fewer channels exist, and fewer suppliers exist, the whole chain can get fragile. If a firm leans on only a few drug makers, a small set of specialist clinics, or a limited list of imported actives, then any delay can spread quickly. Regulatory trouble, or a supply break, can stall product availability and slow down launches. Even newer options might take longer if extra proof is demanded.

Even with that, there is room to try new paths. AI could support acne checks when it works inside teledermatology. This may matter most in places like Gyeonggi, where extra care capacity could help digital steps move without many stops. Firms should join with skin care networks and digital health groups. They should also diversify sourcing so the plan does not hinge on just one partner. Done right, that could speed up rollout and cut dependence on narrow routes.

South Korea Acne Medication Market Report Segmentation

By Product Type

• Topical Retinoids
• Benzoyl Peroxide
• Antibiotics
• Salicylic Acid
• Azelaic Acid
• Hormonal Therapies
• Isotretinoin
• Combination Products
• Oral Antibiotics

By Acne Type

• Comedonal Acne
• Inflammatory Acne
• Cystic Acne
• Nodular Acne
• Mild Acne
• Moderate Acne
• Severe Acne
• Hormonal Acne

By Route of Administration

• Topical
• Oral
• Injectable
• Combination Therapy

By End User

• Hospitals
• Dermatology Clinics
• Pharmacies
• Specialty Clinics
• Homecare
• Online Pharmacies

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Dermatology Clinics
• Drugstores
• Direct Sales